VISEN Pharmaceuticals (HK:2561)
:2561
Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$20.00 - HK$54.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.30B
Enterprise ValueHK$1.70B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta1.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet LeverageReported low-to-moderate leverage and a relatively healthy balance sheet provide durable financial flexibility. This reduces near-term insolvency risk, supports the company's ability to access capital if needed, and cushions ongoing investment while losses persist.
Historically Very Low DebtVery low historical debt through 2022–2024 implies the company entered its recent stress period with conservative leverage. That historical cushion can extend runway, lower immediate refinancing pressure, and provide creditors more confidence over a 2–6 month horizon.
Positive Gross ProfitPositive gross profit in 2024–2025 indicates underlying product or service economics before operating expenses. That unit-level profitability is a durable structural advantage if management can control operating costs and scale sales to improve operating leverage over months.
Bears Say
Persistent Large LossesConsistent, large negative EBIT and net income erode equity and limit internal funding. Over a multi-month horizon this sustains pressure on liquidity and investor support, forces external financing, and reduces the likelihood of near-term profitability absent structural cost or revenue improvements.
Sustained Negative Cash FlowRepeated negative operating and free cash flows create persistent cash burn, increasing reliance on external capital or debt. Worsening cash flow in 2025 makes financing needs more acute, raising dilution or refinancing risk and constraining strategic options over the coming months.
Revenue Decline And Rising DebtA sharp revenue drop in 2025 reduces operating leverage and worsens loss coverage while a 2025 debt step-up raises solvency and refinancing risk. Together these structural trends heighten funding pressure and limit optionality until revenue stabilizes or costs are cut.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$20.00 and its highest was HK$54.00 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.30B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―